Factors affecting recurrence rates after prostatectomy or radiotherapy in localized prostate carcinoma patients with biopsy Gleason score 8 or above

Cancer

Volumn 95, Issue 11, 2002, Pages 2302-2307

  Kupelian, Patrick A ^a,b   Buchsbaum, Jeffrey C ^a   Elshaikh, Mohamed ^a   Reddy, Chandana A ^a   Zippe, Craig ^a   Klein, Eric A ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b M D ANDERSON CANCER CENTER ORLANDO   (United States)

Author keywords

Gleason score; Prognostic factors; Prostate specific antigen; Prostatectomy; Prostatic neoplasms; Radiotherapy

Indexed keywords

ANDROGEN; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BEAM THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE BIOPSY; PROSTATE CARCINOMA; PROSTATECTOMY; SOCIAL ADAPTATION; TREATMENT OUTCOME;

ADULT; AGED; ANDROGEN ANTAGONISTS; BIOPSY; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROSTATECTOMY; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 0036890186     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.10977     Document Type: Article

References (12)

1. Shipley WU, Thames HD, Sandler HM, et al. Radiation therapy for clinically localized prostate carcinoma: A multi-institutional pooled analysis. JAMA. 1999;281:1598-1604.
2. Ohori M, Goad JR, Wheeler TM, Eastham JA, Thompson TC, Scardino PT. Can radical prostatectomy alter the progression of poorly differentiated prostate cancer? J Urol. 1994; 152(5 Pt 2):1843-1849.
3. Lau WK, Bergstralh EJ, Blute ML, Slezak JM, Zincke H. Radical prostatectomy for pathological Gleason 8 or greater prostate cancer: Influence of concomitant pathological variables. J Urol. 2002;167:117-122.
4. Lyons JA, Kupelian PA, Mohan DS, Reddy CA, Klein EA. Importance of high radiation doses (72 Gy or greater) in the treatment of stage T1-T3 adenocarcinoma of the prostate. Urology. 2000;55:85-90.
5. Kupelian PA, Mohan DS, Lyons J, Klein EA, Reddy CA. Higher than standard radiation doses (72 Gy or greater) with or without androgen deprivation in the treatment of localized prostate cancer. Int J Radiat Oncol Biol Phys. 2000;46:567-574.
6. Consensus statement: Guidelines for PSA following radiation therapy. American Society for Therapeutic Radiology and Oncology Consensus Panel. Int J Radiat Oncol Biol Phys. 1997;37:1035-1041.
7. Jhaveri FM, Klein EA, Kupelian PA, Zippe C, Levin HS. Declining rates of extracapsular extension after radical prostatectomy: Evidence for continued stage migration. J Clin Oncol. 1999;17:3167-3172.
8. Hanks GE, Lu JD, Machtay M, et al. RTOG protocol 92-02: A phase III trial of the use of long term total androgen supression following neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys. 2000;48(Suppl.):112.
9. Bolla M, Gonzalez D, Warde P, et al. Immediate hormonal therapy improves locoregional control and survival in patients with locally advanced prostate cancer. Results of a randomized phase III clinical trial of the EORTC radiotherapy and genitourinary tract cancer cooperative groups. J Clin Oncol. 1996;15:238.
10. Bolla M, Gonzalez D, Warde P, et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med. 1997;337:295-300.
11. Horwitz EM, Winter K, Hanks GE, Lawton CA, Russell AH, Machtay M. Subset analysis of RTOG 85-31 and 86-10 indicates an advantage for long-term vs. short-term adjuvant hormones for patients with locally advanced nonmetastatic prostate cancer treated with radiation therapy. Int J Radiat Oncol Biol Phys. 2001;49:947-956.
12. Eastham J, Scardino P. Radical prostatectomy for clinical stage T1 and T2 prostate cancer. In: Vogelzang N, Scardino P, Shipley W, Coffey D. Comprehensive Textbook of Genitourinary Oncology, vol. 42B. Philadelphia: Lippincott Williams and Wilkins, 1999:722-738.